Founded in 1998, Maxigen Biotech Inc. (MBI) is a Taiwanese biomedical company specializing in collagen and hyaluronic acid products, including intra-articular injections and synthetic bone grafts. With CE and FDA certifications and a total of 68 global product approvals, MBI distributes its products across 22 countries. As part of the TCI Group, with major shareholders such as TCI Bio, GIH Group, and NuVasive Inc., MBI recorded a revenue exceeding USD 20 million in 2022. This growth is fueled by strong partnerships with 500 local medical organizations and 175 global customers.
Driving Market Growth Through Innovation and Compliance
MBI maintains confidence in its market position despite economic fluctuations, crediting its success to robust supply chain management, cost control, and ongoing R&D investments. To navigate increasing competition, regulatory hurdles, and evolving market needs, MBI is accelerating its global expansion through timely medical device license applications. With certifications including QMS, ISO13485, and MDSAP, the company underscores its commitment to regulatory excellence. Simultaneously, MBI is attracting top scientific talent and leveraging automation to scale up production, meeting rising global demand.
Commitment to Social Responsibility and Sustainability
With the mission of “Delighting the Life of Human,” MBI integrates social and environmental responsibility into its business practices. The company actively supports corporate social responsibility (CSR) initiatives aligned with the United Nations Sustainable Development Goals (SDGs). These efforts include mountain and beach cleanups, carbon reduction initiatives, and philanthropic activities such as free arthritis clinics in Palau. Additionally, MBI contributes to education in remote areas of Taiwan, helping students gain insights into the medical device industry.
Strengthening Customer Relationships and Global Expansion
MBI’s strategy for global expansion is built on strong customer relationships, selective partnerships, and market adaptability. By collaborating with key opinion leaders (KOLs), leading hospitals, and participating in international exhibitions, MBI remains at the forefront of industry trends. Its focus on superior product quality, expertise in medical device regulations, and comprehensive marketing strategies further differentiates it from competitors. The company’s resilience is reinforced by a customer-centric approach, ensuring adaptability and sustained growth in a competitive industry.
Recognition and Future Aspirations
MBI’s commitment to innovation and business integrity has earned it prestigious recognition, including being named one of Asia’s Leading SMEs by the Asia Corporate Leadership and Sustainability Awards (ACES). This accolade reinforces MBI’s position as a leader in the biomedical sector, inspiring the company to expand its supply chain, strengthen local and international collaborations, and drive further advancements in healthcare technology. As MBI continues to push the boundaries of biomedical innovation, it remains dedicated to shaping the future of global healthcare.
